Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales0.0%
基準 2,027Target2,027Revenue growth
Operating profit margin0.0pt
基準 2,027Target2,027Adjusted EBITA margin
ROIC+2.0pt
基準 2,025Target2,027ROIC
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. For metrics expressed as percentages, differences are shown in percentage points (pt).The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planFY2027 revenue growth rate of 6–8%, adjusted EBITA margin of over 13%, ROIC of 11–13% and Lumada revenue contribution of approximately 45% (as disclosed at Hitachi Investor Day 2025) → FY2025 actual: revenue of ¥3.086 trillion, adjusted EBITA margin of 11.0%, ROIC of 12.0% and Lumada revenue contribution of 43%-0.1%Calculated from the two disclosed figures
Total investment plan¥370 billion (cumulative R&D investment over FY2025–2027)
Investment amount by sectorField R&D Investment / Amount ¥370 billion / Period Cumulative over FY2025–2027
Key initiatives
01Clear business focus on physical AI, starting with strong products
02Accelerating business portfolio transformation
03Expand Customer Zero by leveraging Hitachi's strengths as a manufacturer
04Expand the global business
05Implement AI semiconductors and further strengthen our No. 1 products
06Implement AI semiconductors in collaboration partners' products and deepen co-creation
07Accelerate the validation and creation of solutions through Customer Zero
08Expand the physical AI business centered on globally top-tier products
09Further expand the physical AI business by creating the next globally top-tier products
10Structural reform of the non-Lumada business
11Advance measurement technologies
12Make products more intelligent
Plan assumptionsCustomer market growth rates: facilities CAGR 12%, semiconductors CAGR 13%, medical diagnostics CAGR 10% and pharmaceutical manufacturing CAGR 10% (2025–2030), CAGR of 22% for the AI and software market for facilities (2025–2030), CAGR of 22% for the AI and software market for semiconductor manufacturing (2025–2030), CAGR of 21% for the AI and software market for diagnostics (2025–2030), CAGR of 17% for the AI and software market for pharmaceutical manufacturing (2025–2030)
Segment targetSegment Facilities / Net Sales ¥762.2 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 16% (FY2025) / Growth targets Revenue CAGR of 16% (FY2025–FY2030), Segment Semiconductors / Net Sales ¥305.7 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 17% (FY2025) / Growth targets Revenue CAGR of 15% (FY2025–FY2030), Segment Medical diagnostics / Net Sales ¥285.4 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 15% (FY2025) / Growth targets Revenue CAGR of 11% (FY2025–FY2030), Segment Pharmaceutical manufacturing / Net Sales ¥63.7 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 14% (FY2025) / Growth targets Revenue CAGR of 17% (FY2025–FY2030)
Non-financial targetsIndicator Connected elevators / Target value 650,000 units, global top-tier position / Timing Not disclosed, Indicator Customer base for semiconductor manufacturing equipment / Target value Approximately 70% across 5 companies / Timing 2025, Indicator Biochemistry and immunoassay data / Target value 1 billion people per year cumulatively / Timing Not disclosed, Indicator Scope of automation in testing processes / Target value At least 10x / Timing Not disclosed, Indicator Pharmaceutical industry customer base / Target value 350 companies / Timing Not disclosed, Indicator Development time for digital solutions for semiconductors / Target value Approximately 50% shorter / Timing Not disclosed, Indicator Energy consumption of facilities / Target value Approximately 16% reduction / Timing Not disclosed, Indicator Facility management costs / Target value Approximately 3% improvement per building / Timing Not disclosed, Indicator Biopharmaceutical scale-up period / Target value At least 30% shorter / Timing Not disclosed, Indicator Contribution to production opportunities at pharmaceutical plants / Target value Approximately 10% per plant / Timing Not disclosed
Size of the Target MarketMarket Facilities customer market / Scale ¥201 trillion in 2030 / Growth rate CAGR12%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Semiconductor customer market / Scale ¥240 trillion in 2030 / Growth rate CAGR13%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Medical diagnostics customer market / Scale ¥52 trillion in 2030 / Growth rate CAGR10%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Pharmaceutical manufacturing customer market / Scale ¥120 trillion in 2030 / Growth rate CAGR10%（2025-2030） / Source Calculated from market reports including Grand View Research, Market AI and software market for facilities / Scale Approximately ¥5 trillion in 2030 / Growth rate CAGR22%（2025-2030） / Source Modor Intelligence, Market AI and software market for semiconductor manufacturing / Scale ¥3 trillion in 2030 / Growth rate CAGR22%（2025-2030） / Source DATAINTELO、MarketsandMarkets、Technavio、Virtue Market Research、market.us, Market AI and software market for diagnostics / Scale ¥1.1 trillion in 2030 / Growth rate CAGR21%（2025-2030） / Source Grand View Research, Market AI and software market for pharmaceutical manufacturing / Scale ¥0.6 trillion in 2030 / Growth rate CAGR17%（2025-2030） / Source EXACTITUDE CONSULTANCY
Risks identified by the company
Sharp fluctuations in economic conditions and demand in key markets
Foreign exchange fluctuations
Funding Environment
Share price fluctuations
Shortages and price fluctuations of raw materials and components
The financial condition of counterparties to which credit has been extended
Political and social conditions and various regulations, including trade restrictions, in key markets and business locations, particularly Japan, Asia, the United States and Europe
Response to stricter regulations and other developments relating to climate change measures
Dependence on information systems and management of confidential information
Securing human resources
The ability of Hitachi and its subsidiaries to develop products using new technologies, bring them to market in a timely manner and achieve low-cost production
Natural disasters such as earthquakes and tsunamis, climate change, outbreaks of infectious diseases, and political and social disruption caused by terrorism, conflicts and other events
Estimates, cost fluctuations and contract cancellations relating to long-term construction and other contracts
Intensifying price competition
Fluctuations in the supply and demand of products and other items
The ability of Hitachi and its subsidiaries to respond to fluctuations in the supply and demand of products and other items, foreign exchange rates and raw material prices, and shortages of raw materials and components
Implementation of cost-structure reform initiatives
Strategy relating to strengthening the social innovation business
Execution of acquisitions, business joint ventures and strategic alliances, and the associated costs
Implementation of business restructuring initiatives
Losses relating to investments in equity-method affiliates
Litigation and other legal proceedings against Hitachi, its subsidiaries or equity-method affiliates
Defects and other deficiencies in products and services
Protection of Hitachi’s intellectual property and securing the right to use the intellectual property of other companies
Estimates in calculating liabilities relating to retirement benefits
| Item | Details |
|---|---|
| Plan name | Inspire 2027 |
| Plan period | FY2024-FY2027 |
| Progress against the plan | Annual update |
| Sales Target | 6–8% (FY2027, as disclosed at Hitachi Investor Day 2025) → 6-8%（FY2024-FY2027 CAGR）（0%） |
| Operating profit margin target | Over 13% (FY2027, as disclosed at Hitachi Investor Day 2025) → Over 13% (FY2027)（0%） |
| ROIC target | 12.0% (FY2025 actual) → 11–13% (FY2027 target) |
| Total investment plan | ¥370 billion (cumulative R&D investment over FY2025–2027) |
| Investment amount by sector | Field R&D Investment / Amount ¥370 billion / Period Cumulative over FY2025–2027 |
| Segment target | Segment Facilities / Net Sales ¥762.2 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 16% (FY2025) / Growth targets Revenue CAGR of 16% (FY2025–FY2030), Segment Semiconductors / Net Sales ¥305.7 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 17% (FY2025) / Growth targets Revenue CAGR of 15% (FY2025–FY2030), Segment Medical diagnostics / Net Sales ¥285.4 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 15% (FY2025) / Growth targets Revenue CAGR of 11% (FY2025–FY2030), Segment Pharmaceutical manufacturing / Net Sales ¥63.7 billion (FY2025) / Profit Metrics Adjusted EBITA margin of 14% (FY2025) / Growth targets Revenue CAGR of 17% (FY2025–FY2030) |
| Non-financial targets | Indicator Connected elevators / Target value 650,000 units, global top-tier position / Timing Not disclosed, Indicator Customer base for semiconductor manufacturing equipment / Target value Approximately 70% across 5 companies / Timing 2025, Indicator Biochemistry and immunoassay data / Target value 1 billion people per year cumulatively / Timing Not disclosed, Indicator Scope of automation in testing processes / Target value At least 10x / Timing Not disclosed, Indicator Pharmaceutical industry customer base / Target value 350 companies / Timing Not disclosed, Indicator Development time for digital solutions for semiconductors / Target value Approximately 50% shorter / Timing Not disclosed, Indicator Energy consumption of facilities / Target value Approximately 16% reduction / Timing Not disclosed, Indicator Facility management costs / Target value Approximately 3% improvement per building / Timing Not disclosed, Indicator Biopharmaceutical scale-up period / Target value At least 30% shorter / Timing Not disclosed, Indicator Contribution to production opportunities at pharmaceutical plants / Target value Approximately 10% per plant / Timing Not disclosed |
| Plan assumptions | Customer market growth rates: facilities CAGR 12%, semiconductors CAGR 13%, medical diagnostics CAGR 10% and pharmaceutical manufacturing CAGR 10% (2025–2030), CAGR of 22% for the AI and software market for facilities (2025–2030), CAGR of 22% for the AI and software market for semiconductor manufacturing (2025–2030), CAGR of 21% for the AI and software market for diagnostics (2025–2030), CAGR of 17% for the AI and software market for pharmaceutical manufacturing (2025–2030) |
| Key initiatives | Clear business focus on physical AI, starting with strong products, Accelerating business portfolio transformation, Expand Customer Zero by leveraging Hitachi's strengths as a manufacturer, Expand the global business, Implement AI semiconductors and further strengthen our No. 1 products, Implement AI semiconductors in collaboration partners' products and deepen co-creation, Accelerate the validation and creation of solutions through Customer Zero, Expand the physical AI business centered on globally top-tier products, Further expand the physical AI business by creating the next globally top-tier products, Structural reform of the non-Lumada business, Advance measurement technologies, Make products more intelligent |
| Results under the previous plan | FY2027 revenue growth rate of 6–8%, adjusted EBITA margin of over 13%, ROIC of 11–13% and Lumada revenue contribution of approximately 45% (as disclosed at Hitachi Investor Day 2025) → FY2025 actual: revenue of ¥3.086 trillion, adjusted EBITA margin of 11.0%, ROIC of 12.0% and Lumada revenue contribution of 43% |
| Size of the Target Market | Market Facilities customer market / Scale ¥201 trillion in 2030 / Growth rate CAGR12%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Semiconductor customer market / Scale ¥240 trillion in 2030 / Growth rate CAGR13%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Medical diagnostics customer market / Scale ¥52 trillion in 2030 / Growth rate CAGR10%（2025-2030） / Source Calculated from market reports including Grand View Research, Market Pharmaceutical manufacturing customer market / Scale ¥120 trillion in 2030 / Growth rate CAGR10%（2025-2030） / Source Calculated from market reports including Grand View Research, Market AI and software market for facilities / Scale Approximately ¥5 trillion in 2030 / Growth rate CAGR22%（2025-2030） / Source Modor Intelligence, Market AI and software market for semiconductor manufacturing / Scale ¥3 trillion in 2030 / Growth rate CAGR22%（2025-2030） / Source DATAINTELO、MarketsandMarkets、Technavio、Virtue Market Research、market.us, Market AI and software market for diagnostics / Scale ¥1.1 trillion in 2030 / Growth rate CAGR21%（2025-2030） / Source Grand View Research, Market AI and software market for pharmaceutical manufacturing / Scale ¥0.6 trillion in 2030 / Growth rate CAGR17%（2025-2030） / Source EXACTITUDE CONSULTANCY |
| Risks identified | Sharp fluctuations in economic conditions and demand in key markets, Foreign exchange fluctuations, Funding Environment, Share price fluctuations, Shortages and price fluctuations of raw materials and components, The financial condition of counterparties to which credit has been extended, Political and social conditions and various regulations, including trade restrictions, in key markets and business locations, particularly Japan, Asia, the United States and Europe, Response to stricter regulations and other developments relating to climate change measures, Dependence on information systems and management of confidential information, Securing human resources, The ability of Hitachi and its subsidiaries to develop products using new technologies, bring them to market in a timely manner and achieve low-cost production, Natural disasters such as earthquakes and tsunamis, climate change, outbreaks of infectious diseases, and political and social disruption caused by terrorism, conflicts and other events, Estimates, cost fluctuations and contract cancellations relating to long-term construction and other contracts, Intensifying price competition, Fluctuations in the supply and demand of products and other items, The ability of Hitachi and its subsidiaries to respond to fluctuations in the supply and demand of products and other items, foreign exchange rates and raw material prices, and shortages of raw materials and components, Implementation of cost-structure reform initiatives, Strategy relating to strengthening the social innovation business, Execution of acquisitions, business joint ventures and strategic alliances, and the associated costs, Implementation of business restructuring initiatives, Losses relating to investments in equity-method affiliates, Litigation and other legal proceedings against Hitachi, its subsidiaries or equity-method affiliates, Defects and other deficiencies in products and services, Protection of Hitachi’s intellectual property and securing the right to use the intellectual property of other companies, Estimates in calculating liabilities relating to retirement benefits |
| Publication date | 9 June 2026 |
Items this document does not state (9)
Operating profit targetNet income targetROE targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The strategy calls for capturing strong growth in Lumada driven by AI demand, concentrating management resources on areas with robust AI investment, expanding the physical AI business and accelerating business portfolio transformation.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.